BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27783548)

  • 1. Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia.
    MacEwan JP; Forma FM; Shafrin J; Hatch A; Lakdawalla DN; Lindenmayer JP
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1349-1361. PubMed ID: 27783548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia.
    Shafrin J; Schwartz TT; Lakdawalla DN; Forma FM
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1285-1291. PubMed ID: 27783545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D; Rubin DT; Mease P; Mittal M; Liu H; Davis M; Ganguli A; Fendrick AM
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annual costs among patients with major depressive disorder and the impact of key clinical events.
    Cutler AJ; Keyloun KR; Higa S; Park J; Bonafede M; Gillard P; Jain R
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1335-1343. PubMed ID: 36427344
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics.
    Pilon D; Patel C; Lafeuille MH; Zhdanava M; Lin D; Côté-Sergent A; Rossi C; Lefebvre P; Joshi K
    J Manag Care Spec Pharm; 2021 Jul; 27(7):904-914. PubMed ID: 34185557
    [No Abstract]   [Full Text] [Related]  

  • 7. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM; Brixner D; Rubin DT; Mease P; Liu H; Davis M; Mittal M
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
    Pauly NJ; Talbert JC; Brown J
    J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV.
    Dunn K; Lafeuille MH; Jiao X; Romdhani H; Emond B; Woodruff K; Pesa J; Tandon N; Lefebvre P
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1040-1051. PubMed ID: 29877140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
    Rajagopalan K; Wade S; Meyer N; Loebel A
    Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
    Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
    J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia.
    El Khoury AC; Pilon D; Morrison L; Shak N; Llaneza A; Kim E; Lefebvre P
    J Manag Care Spec Pharm; 2020 Feb; 26(2):176-185. PubMed ID: 32011960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.
    Hidalgo-Mazzei D; Berk M; Cipriani A; Cleare AJ; Florio AD; Dietch D; Geddes JR; Goodwin GM; Grunze H; Hayes JF; Jones I; Kasper S; Macritchie K; McAllister-Williams RH; Morriss R; Nayrouz S; Pappa S; Soares JC; Smith DJ; Suppes T; Talbot P; Vieta E; Watson S; Yatham LN; Young AH; Stokes PRA
    Br J Psychiatry; 2019 Jan; 214(1):27-35. PubMed ID: 30520709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence, health care utilization, and costs between long-acting injectable and oral antipsychotic medications in South Carolina Medicaid beneficiaries with schizophrenia.
    Cai C; Kozma C; Patel C; Benson C; Yunusa I; Zhao P; Reeder G; Narasimhan M; Bank RL
    J Manag Care Spec Pharm; 2024 Jun; 30(6):549-559. PubMed ID: 38824623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder.
    Broder MS; Greene M; Chang E; Hartry A; Yan T; Yermilov I
    J Med Econ; 2019 Jan; 22(1):63-70. PubMed ID: 30376745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.